Restricted accessResearch articleFirst published online 2020-07
Correlation of Tumor Necrosis Factor-α −308G>A Polymorphism with Susceptibility,Clinical Manifestations,and Severity in Behçet Syndrome: Evidences from an Italian Genetic Case–Control Study
To investigate the association between a functional drug-response tumor necrosis factor (TNF)α gene polymorphism (at the positions of −308; rs1800629; NG_007462.1:g.4682G>A) and both disease susceptibility and clinical manifestations in a cohort of 130 Italian patients with Behçet syndrome (BS). A group of 100 ethnically, age, and gender matched healthy controls (HC) was also recruited. Genotyping was performed using molecular (amplification and direct sequencing) and in silico methods. The genotype distribution of BS patients and HC underlined a lower percentage of wild-type GG genotype in BS patients versus HC (106/130 patients, 81.5% vs. 91/100 HC, 91%; p < 0.05), while the heterozygous genotype (GA) was identified in 24/130 patients (18.5%) versus 9/100 HC (9%) (p < 0.05). GA genotype was significantly associated with the disease (odds ratio = 2.29, 95% confidence interval 1.01–5.18). No significant association was recognized between the single nucleotide polymorphism (SNP) and the BS clinical manifestations, as well as with disease severity (Krause's index). We found statistically significant higher frequency of TNFα rs1800629 GA genotype in patients than in controls. No significant association was recognized between the polymorphism and the clinical parameters, as well as between the SNP and the disease severity. Our data need to be confirmed in larger cohort of patients and matched controls.
Get full access to this article
View all access options for this article.
References
1.
AbdolmohammadiR., and BonyadiM. (2017). Polymorphisms of promoter region of TNF-α gene in Iranian Azeri Turkish patients with Behçet's disease. J Korean Med Sci, 32, 33–37.
2.
AflatoonianM., MoghimiM., Akbarian-BafghiM.J., Morovati-SharifabadM., JarahzadehM.H., and NeamatzadehH. (2019). Association of TNF-α-308G>A polymorphism with susceptibility to celiac disease: a systematic review and meta-analysis. Arq Gastroenterol, 56, 88–94.
3.
Al-OkailyF., ArfinM., Al-RashidiS., Al-BalawiM., and Al-AsmariA. (2015). Inflammation-related cytokine gene polymorphisms in Behçet's disease. J Inflamm Res, 8, 173–180.
4.
AteşA, KinikliG., DüzgünN, and DumanM. (2006). Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behçet's disease. Rheumatol Int, 26, 348–353.
5.
AteşO, DalyanL., HatemiG., HamuryudanV., and Topal-SarıkayaA. (2010). Analyses of functional IL10 and TNF-α genotypes in Behçet's syndrome. Mol Biol Rep, 37, 3637–3641.
6.
BadanoI., StietzS.M., SchurrT.G., PicconiA.M., FeketeD., QuinteroI.M., et al. (2012). Analysis of TNFalpha promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol, 53, 54–59.
7.
BekS., BojesenA.B., NielsenJ.V., SodeJ., BankS., VogelU., et al. (2017). Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J, 17, 403–411.
8.
BonyadiM., JahanafroozZ., EsmaeiliM., KolahiS., KhabaziA., EbrahimiA.A., et al. (2009). TNF-alpha gene polymorphisms in Iranian Azeri Turkish patients with Behcet's Disease. Rheumatol Int, 30, 285–289.
9.
Burillo-SanzS., Montes-CanoM.A., García-LozanoJ.R., Ortiz-FernándezL., Ortego-CentenoN., and García-HernándezF.J. (2017). Mutational profile of rare variants in inflammasome-related genes in Behçet disease: a next generation sequencing approach. Sci Rep 7,453.
10.
DengY., ZhuW., and ZhouX. (2018). Immune regulatory genes are major genetic factors to Behcet disease: systematic review. Open Rheumatol J, 12, 70–85.
11.
Duymaz-TozkirJ., GülA, UyarF.A., OzbekU., and Saruhan-DireskeneliG. (2003). Tumour necrosis factor-alpha gene promoter region -308 and -376 G—>A polymorphisms in Behçet's disease. Clin Exp Rheumatol, 21, S15–S18.
12.
GulA. (2014). Genetics of Behçet's disease: lessons learned from genomewide association studies. Curr Opin Rheumatol, 26, 56–63.
13.
GulA. (2015). Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Semin Immunopathol, 37, 413–418.
14.
KamounM., ChelbiH., HoumanM.H., LachebJ., and HamzaouiK. (2007). Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease. Hum Immunol, 68, 201–205.
15.
Khaib Dit NaibO., AribiM., IdderA., ChialiA., SairiH., TouitouI., et al. (2013). Association analysis of IL10, TNF-α, and IL23R-IL12RB2 SNPs with Behçet's disease risk in Western Algeria. Front Immunol, 4, 342.
16.
KirinoY., BertsiasG., IshigatsuboY., MizukiN., Tugal-TutkunI., SeyahiE., et al. (2013). Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet, 45, 202–207.
17.
Konè-PautI., SanchezE., Le QuellecA., MannaR., and TouitouI. (2007). Autoinflammatory gene mutations in Behçet's disease. Ann Rheum Dis, 66, 832–834.
18.
KrauseI., RoseY., KaplanI., MiloG., GuedjD., MoladY., et al. (1999). Recurrent aphthous stomatitis in Behçet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med, 28, 193–196.
19.
LecceseP., PadulaM.C., SantospiritoE.V., ColucciR., LascaroN., and D'AngeloS. (2019). HLA-B*51 subtypes molecular analysis in a series of Italian patients with Behçet's syndrome. Joint Bone Spine, 86, 807–808.
20.
LeeE.B., KimJ.Y., LeeY.J., ParkM.H., and SongY.W. (2003). TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum Immunol, 64, 614–620.
21.
LiangY., XuW.D., ZhangM., QiuL.J., NiJ., WangX.S., et al. (2013). Meta-analysis of association between cytokine gene polymorphisms and Behcet's disease risk. Int J Rheum Dis, 16, 616–624.
22.
LinL., HongsongY., YanniJ., DengB., BaiL., KijlstraA., et al. (2016). Genetic variations of NLR family genes in Behcet's Disease. Sci Rep, 6, 20098.
23.
MarotteH., ArnaudB., DiasparraJ., ZrioualS., and MiossecP. (2008). Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at −308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum, 58, 1258–1263.
24.
OmbrelloM.J., KastnerD.L., and RemmersE.F. (2015). Endoplasmic reticulum-associated amino-peptidase 1 and rheumatic disease: genetics. Curr Opin Rheumatol, 27, 349–356.
25.
O'RiellyD.D., RoslinN.M., BeyeneJ., PopeA., and RahmanP. (2009). TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J, 9, 161–167.
26.
PadulaM.C., LecceseP., LascaroN., CarboneT., GilioM., PadulaA.A., et al. (2019). Genotyping of Italian patients with Behçet syndrome identified two novel ERAP1 polymorphisms using sequencing-based approach. Hum Immunol, 80, 335–338.
27.
ParkK., KimN., NamJ., BangD., and LeeE.S. (2006). Association of TNFA promoter region haplotype in Behçet's Disease. J Korean Med Sci, 21, 596–601.
28.
PavyS., ToonenE.J., Miceli-RichardC., BarreraP., van RielP.L., CriswellL.A., et al. (2010). Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis, 69, 1022–1028.
29.
RadouaneA., OudghiriM., ChakibA., BennaniS., TouitouI., and Barat-HouariM. (2012). SNPs in the TNF-α gene promoter associated with Behcet's disease in Moroccan patients. Rheumatology (Oxford), 51, 1595–1599.
30.
SousaI., ShahramF., FranciscoD., DavatchiF., AbdollahiB.S., GhaderibarmiF., et al. (2015). Brief report: association of CCR1, KLRC4, IL12A-AS1, STAT4, and ERAP1 with Behçet's disease in Iranians. Arthritis Rheumatol, 67, 2742–2748.
31.
StorzK., LöfflerJ., KochS., VontheinR., ZouboulisC.C., FreskoI., et al. (2008). IL-6 receptor, IL-8 receptor and TNF-alpha238 (G/A) polymorphisms are not associated with Behçet's disease in patients of German or Turkish origin. Clin Exp Rheumatol, 26, S103–S106.
32.
TakeuchiM., KastnerD.L., and RemmersE.F. (2015). The immunogenetics of Behçet's disease: a comprehensive review. J Autoimmun, 64, 137–148.
33.
ToumaZ., FarraC., HamdanA., ShamseddeenW., UthmanI., HouraniH., et al. (2010). TNF polymorphisms in patients with Behçet disease: a meta-analysis. Arch Med Res, 41, 142–146.
34.
WangL., MaK., WangZ., MouY., MaL., and GuoY. (2015). Association between tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical cancer. Int J Clin Exp Med, 8, 2108–2117.
35.
WangL., QuG., WuW., TangX., and SunY. (2018). Association between tumor necrosis factor-α-308G/A gene polymorphism and susceptibility to pre-eclampsia: an updated meta-analysis. Cytokine, 111, 278–286.
36.
WeichslerB., DavatchiF., MizushimaY., HamzaM., DilsenN., et al. (1990). Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet, 335, 1078–1080.
37.
YangF., WeiK., QinZ., ShaoC., ShuY., and ShenH. (2019). Association between TNF-ɑ-308G/A polymorphism and esophageal cancer risk: an updated meta-analysis and trial sequential analysis. J Cancer, 10, 1086–1096.
38.
YükselS., ErenE., HatemiG. S, ahillioğluA.C., GültekinY., and DemirözD. (2013). Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet's syndrome patients. Int Immunol, 26, 71–81.
39.
ZengZ., DuanZ., ZhangT., WangS., LiG., GaoJ., et al. (2013). Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol, 23, 489–495.
40.
ZhangM., XuW.D., WenP.F., LiangY., LiuJ., PanH.F., et al. (2013). Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease: an updated meta-analysis. Mol Vis, 19, 1913–1924.
41.
ZhangY., CaoY., XinL., GaoN., and LiuB. (2018). Association between rs1800629 polymorphism in tumor necrosis factor-α gene and dilated cardiomyopathy susceptibility: evidence from case-control studies. Medicine (Baltimore), 97, e13386.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
